David Fredrickson
EVP, Oncology Business UnitAstraZeneca
PharmaceuticalsView Profile →President, US · Novartis
Victor Bulto is president of Novartis’s US business. His earlier roles span European neuroscience, Alcon pharmaceuticals and US immunology and dermatology before broader American commercial leadership.
Last reviewed: Nov 15, 2026
Victor Bulto is president of Novartis’s US business. His earlier roles span European neuroscience, Alcon pharmaceuticals and US immunology and dermatology before broader American commercial leadership.
Before joining Novartis, Bulto worked in medical-device sales. His education combines chemistry and chemical engineering at Ramon Llull University with postgraduate study in health economics and pharmacoeconomics and an MBA.
His Spanish commercial roles included respiratory and osteoarticular marketing and neuroscience franchise leadership. From 2013 to 2016 he headed the Neuroscience franchise for Novartis’s European region.
Bulto moved into US leadership in 2016 as vice president and head of Alcon Pharmaceuticals. He then led the US Immunology & Dermatology franchise from 2017 to 2019, before becoming president of Novartis Pharmaceuticals Corporation.
He took charge of the broader US unit in 2022. The company’s annual report records his executive-committee appointment from May 1 that year. His current external appointments include the boards of Labcorp and the Biotechnology Innovation Organization and the advisory board of the Schaeffer Center for Health Policy & Economics.
Master of Business Administration — ESADE Business School.
Master’s degree — Pompeu Fabra University — Health Economics and Pharmacoeconomics.
Master’s degree — Ramon Llull University — Chemical Engineering.
Bachelor’s degree — Ramon Llull University — Chemistry.